Overview

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

Status:
Recruiting
Trial end date:
2023-10-29
Target enrollment:
Participant gender:
Summary
Multiparametric assesment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study
Phase:
Phase 2
Details
Lead Sponsor:
Alfredo Berruti